Oncternal Therapeutics Inc. (NASDAQ: ONCT): Decline Of -372.97% Looks Weak With A Stock Forecast 2021 – Marketing Sentinel
Home  »  Company   »  Oncternal Therapeutics Inc. (NASDAQ: ONCT): Declin...

Oncternal Therapeutics Inc. (NASDAQ: ONCT): Decline Of -372.97% Looks Weak With A Stock Forecast 2021

In today’s recent session, 0.7 million shares of the Oncternal Therapeutics Inc. (NASDAQ:ONCT) have been traded, and its beta is 1.61. Most recently the company’s share price was $4.44, and it changed around $0.29 or 6.99% from the last close, which brings the market valuation of the company to $203.43M. ONCT at last check was trading at a discount to its 52-week high of $10.56, offering almost -137.84% off that amount. The share price’s 52-week low was $1.49, which indicates that the recent value has risen by an impressive 66.44% since then. We note from Oncternal Therapeutics Inc.’s average daily trading volume that its 10-day average is 0.65 million shares, with the 3-month average coming to 1.12 million.

Oncternal Therapeutics Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.70. If we narrow it down even further, the data shows that 0 out of 4 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended ONCT as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Oncternal Therapeutics Inc. is expected to report earnings per share of -$0.14 for the current quarter.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Oncternal Therapeutics Inc. (NASDAQ:ONCT) trade information

Instantly ONCT has been showing a green trend so far today with a performance of 6.99% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 4.43 on Tuesday, 07/20/21 decreased the stock’s daily price by -0.23%. The company’s shares are currently down -15.31% year-to-date, but still down -1.89% over the last five days. On the other hand, Oncternal Therapeutics Inc. (NASDAQ:ONCT) is -21.25% down in the 30-day period. We can see from the shorts that 1.26 million shares have been sold at a short interest cover period of 1.03 day(s).

The consensus price target as assigned by Wall Street analysts is $15.50, which translates to bulls needing to increase their stock price by 71.35% from its current value. Analyst projections state that ONCT is forecast to be at a low of $9.00 and a high of $21.00. In order for the stock price to hit the forecast high, the stock would need to plunge -372.97% from its current level, while the stock would need to crash -102.7% from its current level to reach the projected low.

Oncternal Therapeutics Inc. (ONCT) estimates and forecasts

Oncternal Therapeutics Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -28.32 percent over the past six months and at a 30.59% annual growth rate that is well above the industry average of 16.70%. The year-over-year growth rate is expected to be 36.60%, up from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of $1.09 million in revenue for the current quarter. 4 analysts expect Oncternal Therapeutics Inc. to make $1.23 million in revenue for the quarter ending Sep 2021. The company’s sales for the same quarters a year ago were $623k and $620k respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 75.00%. Forecasts for the next quarter put sales growth at 98.40%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 8.60%. Oncternal Therapeutics Inc. earnings are expected to increase by 74.40% in 2021, but the outlook is negative 0.00% per year for the next five years.

ONCT Dividends

Oncternal Therapeutics Inc.’s next quarterly earnings report is expected to be released on May 06.

Oncternal Therapeutics Inc. (NASDAQ:ONCT)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 11.82% of Oncternal Therapeutics Inc. shares, and 25.20% of them are in the hands of institutional investors. The stock currently has a share float of 28.58%. Oncternal Therapeutics Inc. stock is held by 85 institutions, with Vanguard Group, Inc. (The) being the largest institutional investor. By Mar 30, 2021, it held 3.57% of the shares, which is about 1.76 million shares worth $14.66 million.

Blackrock Inc., with 2.18% or 1.08 million shares worth $8.95 million as of Mar 30, 2021, holds the second largest percentage of outstanding shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Mar 30, 2021. The former held 1.06 million shares worth $8.84 million, making up 2.15% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 0.62 million shares worth around $5.19 million, which represents about 1.26% of the total shares outstanding.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

173226

100% free. stop anytime no spam